174 related articles for article (PubMed ID: 21659357)
21. The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
Ho PA; Alonzo TA; Gerbing RB; Kuhn J; Pollard JA; Hirsch B; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2014 Jan; 61(1):81-8. PubMed ID: 23956224
[TBL] [Abstract][Full Text] [Related]
22. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Langer C; Marcucci G; Holland KB; Radmacher MD; Maharry K; Paschka P; Whitman SP; Mrózek K; Baldus CD; Vij R; Powell BL; Carroll AJ; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2009 Jul; 27(19):3198-204. PubMed ID: 19451432
[TBL] [Abstract][Full Text] [Related]
23. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K; Damm F; Göhring G; Görlich K; Heuser M; Schäfer I; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar AA; Fiedler W; Kirchner HH; Brugger W; Zucknick M; Schlegelberger B; Heil G; Ganser A; Krauter J
J Clin Oncol; 2010 May; 28(14):2356-64. PubMed ID: 20368538
[TBL] [Abstract][Full Text] [Related]
24. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
25. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
26. Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.
Renneville A; Boissel N; Helevaut N; Nibourel O; Terré C; Pautas C; Gardin C; Thomas X; Turlure P; Reman O; Berthon C; Dombret H; Castaigne S; Preudhomme C
Leukemia; 2011 Dec; 25(12):1918-21. PubMed ID: 21760594
[No Abstract] [Full Text] [Related]
27. [Association of WT1 rs16754 polymorphism with clinical features and prognosis in patients with acute myeloid leukemia].
Xu J; Li L; Li J; Chen Y; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):898-902. PubMed ID: 27801325
[TBL] [Abstract][Full Text] [Related]
28. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia.
Hollink IH; van den Heuvel-Eibrink MM; Zimmermann M; Balgobind BV; Arentsen-Peters ST; Alders M; Willasch A; Kaspers GJ; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
J Clin Oncol; 2010 Oct; 28(28):e523-6; author reply e527-e528. PubMed ID: 20644087
[No Abstract] [Full Text] [Related]
29. [Expression of
Du D; Zhu L; Wang Y; Ye X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 May; 48(1):50-57. PubMed ID: 31102358
[TBL] [Abstract][Full Text] [Related]
30.
Koczkodaj D; Zmorzyński S; Grygalewicz B; Pieńkowska-Grela B; Styk W; Popek-Marciniec S; Filip AA
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407481
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.
Zidan MA; Kamal Shaaban HM; Elghannam DM
Hematology; 2014 Jul; 19(5):267-74. PubMed ID: 24074521
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Paschka P; Holland KB; Schwind S; Wu YZ; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Moore JO; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Aug; 116(5):788-92. PubMed ID: 20442368
[TBL] [Abstract][Full Text] [Related]
33. WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Miglino M; Colombo N; Pica G; Grasso R; Clavio M; Bergamaschi M; Ballerini F; Ghiso A; Ghiggi C; Mitscheunig L; Beltrami G; Cagnetta A; Vignolo L; Lucchetti MV; Aquino S; Pierri I; Sessarego M; Carella AM; Gobbi M
Leuk Lymphoma; 2011 Oct; 52(10):1961-9. PubMed ID: 21942328
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
[TBL] [Abstract][Full Text] [Related]
35. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Renneville A; Boissel N; Zurawski V; Llopis L; Biggio V; Nibourel O; Philippe N; Thomas X; Dombret H; Preudhomme C
Cancer; 2009 Aug; 115(16):3719-27. PubMed ID: 19536888
[TBL] [Abstract][Full Text] [Related]
36. WT1 mutations and polymorphisms in Southeast Asian acute myeloid leukemia.
Lauhakirti D; Sritana N; Boonthimat C; Promsuwicha O; Auewarakul CU
Exp Mol Pathol; 2011 Dec; 91(3):682-6. PubMed ID: 21798259
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA expression in cytogenetically normal acute myeloid leukemia.
Marcucci G; Radmacher MD; Maharry K; Mrózek K; Ruppert AS; Paschka P; Vukosavljevic T; Whitman SP; Baldus CD; Langer C; Liu CG; Carroll AJ; Powell BL; Garzon R; Croce CM; Kolitz JE; Caligiuri MA; Larson RA; Bloomfield CD
N Engl J Med; 2008 May; 358(18):1919-28. PubMed ID: 18450603
[TBL] [Abstract][Full Text] [Related]
38. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.
Megías-Vericat JE; Herrero MJ; Rojas L; Montesinos P; Bosó V; Moscardó F; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2016 Feb; 16(1):30-40. PubMed ID: 26644203
[TBL] [Abstract][Full Text] [Related]
39. Use of Wilms Tumor 1 Gene Expression as a Reliable Marker for Prognosis and Minimal Residual Disease Monitoring in Acute Myeloid Leukemia With Normal Karyotype Patients.
Marjanovic I; Karan-Djurasevic T; Ugrin M; Virijevic M; Vidovic A; Tomin D; Suvajdzic Vukovic N; Pavlovic S; Tosic N
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):312-319. PubMed ID: 28163010
[TBL] [Abstract][Full Text] [Related]
40. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
